Kadmon Holdings, Inc.: directors' dealings · United States · SEC (Form 4)

About Kadmon Holdings, Inc.

Kadmon Holdings, Inc. was a US biopharmaceutical company listed on the Nasdaq market in the United States before being acquired by Sanofi in November 2021. For French, Belgian, and Swiss investors, Kadmon is best understood as a specialty biotech: a research-driven platform focused on high-unmet-need diseases, with value creation tied to clinical development, regulatory execution, and ultimately commercialization or strategic M&A. The company’s roots go back to the 2010s, when Kadmon Pharmaceuticals and the broader Kadmon structure were built out into Kadmon Holdings, followed by a Nasdaq listing in 2016. Its historical headquarters was in New York, New York, placing it in one of the most important US biopharma clusters. Before the acquisition, Kadmon combined internal clinical development capabilities with external in-licensing and collaboration strategies to build a pipeline spanning several therapeutic areas. Kadmon’s key value driver was REZUROCK (belumosudil), a therapy approved in the United States for certain patients with chronic graft-versus-host disease after failure of prior systemic therapies. This product gave Kadmon a meaningful commercial profile compared with many pre-revenue biotech peers and became the centerpiece of the Sanofi transaction. More broadly, Kadmon’s strategy was centered on complex, often chronic or immunology-related diseases, where competition is fierce but where clinically differentiated assets can still build durable market positions if they show clear efficacy and tolerability. Geographically, Kadmon was primarily a US-focused company, with operations, regulatory activity, and early commercial traction concentrated in its domestic market. Any broader international opportunity depended on further clinical data, regulatory approvals, and the ability to support reimbursement and market access outside the United States. Its competitive landscape included both specialty biopharma peers and larger pharmaceutical groups with the scale to accelerate launches and global distribution. The most important recent development was Sanofi’s definitive agreement announced in September 2021 to acquire Kadmon for $9.50 per share in cash, implying an equity value of about $1.9 billion. Sanofi completed the acquisition on November 9, 2021. From an equity analyst perspective, Kadmon is now primarily a historical case study of value creation in specialty pharma: a Nasdaq-listed US biotech that moved from development-stage uncertainty to regulatory validation, commercial launch, and an eventual strategic exit.